Onchocerciasis clinical trials
The registry lists 35 studies for Onchocerciasis across more than 10 countries. 7 are recruiting or about to start. 24 of them are mainly about Onchocerciasis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30.
Get an email when these change. Save the Onchocerciasis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Washington University School of Medicine (5) · Medicines Development for Global Health (5) · Universiteit Antwerpen (3) · University Hospitals Cleveland Medical Center (2) · Liverpool School of Tropical Medicine (2) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (2) · Drugs for Neglected Diseases (2) · Bayer (1)
What is being tested here
Drugs under test in Onchocerciasis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3, phase 3 first
- Dec 202621-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia · Phase 3 · Programme National de Lutte contre l'Onchocercose, Republic of the Congo
- Feb 2027Integrating Mental Health Into Neglected Tropical Disease Care in Ghana · Liverpool School of Tropical Medicine
- Jul 2027Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations · Uwemedimo Friday Ekpo
Who these studies take
Of the 3 Onchocerciasis studies recruiting now, 2 (67%) set no upper age limit and 1 (33%) stop at 75 or younger. 2 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (67%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (67%) | 2 (67%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 2 (67%) | 2 (67%) |
| 85 | 2 (67%) | 2 (67%) |
Across all 35 studies, recruiting or not: 51% stop at 75 or younger and 40% at 65; 57% take children; 0% are for women only and 3% for men only; 40% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 35 of 35. search them.
- Expanding Access to Preventive Chemotherapy Among Mobile and Migrant PopulationsRecruitingNCT07707817Not applicable1 country
- Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health WorkersNot yet recruitingNCT07506967Not applicable5 countries
- Integrating Mental Health Into Neglected Tropical Disease Care in GhanaNot yet recruitingNCT07248462Not applicable
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical DiseasesRecruitingNCT07145736Phase 41 country
- 21-day Double-blind Trial of Albendazole in Adults With Loa Loa MicrofilaremiaNot yet recruitingNCT06613997Phase 3
- A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected SubjectsRecruitingNCT06252961Phase 2/31 country
- Onchocerciasis-Associated Epilepsy, an Explorative Case-control StudyNot yet recruitingNCT058685511 country
- Host Response to Infection and Treatment in Filarial DiseasesActive, not recruitingNCT000012301 country
- Development of a New Rapid Diagnostic Test to Support Onchocerciasis EliminationCompletedNCT06350851Not applicable1 country
- Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant AlbendazoleCompletedNCT04311671Phase 32 countries
- Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisActive, not recruitingNCT03876262Phase 31 country
- Safety and Efficacy of Novel Combination Regimens for Treatment of OnchocerciasisActive, not recruitingNCT06070116Phase 21 country
- A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 YearsCompletedNCT03962062Phase 11 country
- Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central AfricaWithdrawnNCT04035174Not applicable1 country
- A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy ParticipantsCompletedNCT06412926Phase 11 country
- Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus InfectionTerminatedNCT04913610Phase 21 country
- Clinical Trial of Rifampin and Azithromycin for the Treatment of River BlindnessCompletedNCT00127504Phase 21 country
- Safety and Efficacy of IDA for OnchocerciasisCompletedNCT04188301Phase 21 country
- Emodepside Phase II Trial for Treatment of OnchocerciasisActive, not recruitingNCT05180461Phase 22 countries
- Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South SudanCompletedNCT057500431 country
- Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic AreaCompletedNCT05749653Not applicable1 country
- Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide DrugTerminatedNCT05084560Phase 11 country
- PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole TabletsCompletedNCT04920292Phase 11 country
- Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus InfectionCompletedNCT00300768Phase 21 country
- Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for LiberiaCompletedNCT019054361 country
- Ocular Changes After Ivermectin - (DOLF IVM/Oncho)CompletedNCT03517462Not applicable1 country
- First in Man Clinical Trial of Emodepside (BAY 44-4400)CompletedNCT02661178Phase 11 country
- Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, GhanaCompletedNCT02078024Phase 31 country
- Ivermectin Treatment in Patients With Onchocerciasis-associated EpilepsyCompletedNCT03052998Phase 41 country
- Prevalence of LF Infection in Districts Not Included in LF Control ActivitiesCompletedNCT031314011 country
- Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga DistrictStatus unknownNCT036539751 country
- Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)CompletedNCT020320431 country
- Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus InfectionCompletedNCT00790998Phase 33 countries
- IVM Alone vs ALB + IVM Against OnchocerciasisCompletedNCT03238131Phase 31 country
- Pediatric Pharmacokinetics And Safety Study Of MoxidectinWithdrawnNCT01035619Phase 2